The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA clearance granted for Hydrashift 2/4 daratumumab assay
On 24 January 2018, Sebia, a world leader in Multiple Myeloma (MM) in-vitro diagnostic (IVD) testing and monitoring, announced that its Hydrashift 2/4 daratumumab assay has been granted clearance for use by the US Food and Drug Administration (FDA). This assay can be used to monitor MM patients treated with daratumumab (Darzalex).
Daratumumab, along with other humanized monoclonals, are known to interfere with native antibodies in immunofixation (IF) tests and lead to misinterpretation of patient response data. Hydrashift 2/4 daratumumab is used with the Hydragel Immunofixation (IF) assay to enable qualitative detection of endogenous M-protein in human serum, and specifically removes daratumumab interference.
This Hydrashift 2/4 daratumumab assay was developed in a collaboration between Sebia and Janssen Biotech, and provides an improved means of monitoring MM patients, in accordance with the latest recommendations from the International Myeloma Working Group (IMWG).
References